文献速递淋巴瘤白血病

PPAR-δ促进慢性淋巴细胞白血病细胞在能量不利条件下的存活

PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.
PubMed 文献 · Leukemia · 2017-01-04

该研究探讨PPARδ在慢性淋巴细胞白血病(CLL)细胞生存中的作用。生物信息学分析显示CLL细胞PPARD表达高于正常淋巴细胞和其他血液肿瘤,PPARδ蛋白水平与临床评分直接相关。转基因表达PPARδ可增强CD5+ Daudi细胞和原代CLL细胞在应激条件下的生长和存活,而遗传缺失或合成PPARδ拮抗剂可逆转低糖存活,提示靶向PPARδ可能有益于CLL治疗。

要点

  • CLL细胞中PPARD表达高于正常淋巴细胞和其他血液肿瘤。
  • PPARδ蛋白水平与CLL临床评分直接相关。
  • PPARδ增强CLL细胞在低糖、缺氧、细胞毒药物等应激下的存活。

核心结论

  • PPARδ通过减少氧化应激和增加代谢效率使CLL细胞适应恶劣微环境,靶向PPARδ可能有益于CLL治疗。

研究设计与样本

  • 研究类型未明确报告,涉及生物信息学分析、转基因表达和原代CLL细胞实验。

主要发现

  • 生物信息学分析显示CLL细胞PPARD表达高于正常淋巴细胞和其他血液肿瘤。
  • CLL细胞PPARδ蛋白水平与临床评分直接相关。
  • 转基因表达PPARδ增加CD5+ Daudi细胞和原代CLL细胞在耗竭培养基、低糖、缺氧和细胞毒药物应激条件下的生长和存活。
  • 糖皮质激素和合成PPARδ激动剂上调PPARD表达并保护Daudi和原代CLL细胞免受代谢应激。
  • 低糖存活与抗氧化表达增加、底物利用和线粒体性能提高相关,并被遗传缺失和合成PPARδ拮抗剂逆转。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting the mechanisms that allow chronic lymphocytic leukemia (CLL) cells to survive in harsh cancer microenvironments should improve patient outcomes. The nuclear receptor peroxisome proliferator activated receptor delta (PPARδ) sustains other cancers, and in silico analysis showed higher PPARD expression in CLL cells than normal lymphocytes and other hematologic cancers. A direct association was found between PPARδ protein levels in CLL cells and clinical score. Transgenic expression of PPARδ increased the growth and survival of CD5+ Daudi cells and primary CLL cells in stressful conditions including exhausted tissue culture media, low extracellular glucose, hypoxia and exposure to cytotoxic drugs. Glucocorticoids and synthetic PPARδ agonists up-regulated PPARD expression and also protected Daudi and primary CLL cells from metabolic stressors. Survival in low glucose was related to increased antioxidant expression, substrate utilization and mitochondrial performance, and was reversed by genetic deletion and synthetic PPARδ antagonists. These findings suggest PPARδ conditions CLL cells to survive in harsh microenvironmental conditions by reducing oxidative stress and increasing metabolic efficiency. Targeting PPARδ may be beneficial in the treatment of CLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Li YJ, Sun L, Shi Y, et al. PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions. Leukemia. 2017. PMID: 28050012. doi:10.1038/leu.2016.395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。